The rising fungi infections such as athlete’s foot to boost the Antifungal Drugs Market growth

 

Antifungal Drugs Market

Global Antifungal Drugs Market, by Drug Type (Echinocandins, Polyenes, Allylamines, Azoles, and Others), by Indication (Aspergillosis, Dermatophytosis, Candidiasis, Mucormycosis, and Others), by Dosage Form (Powders, Ointments, Drugs, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028

The global Antifungal Drugs Market is estimated to be valued at US$ XX million in XXX and is expected to exhibit a CAGR of XX% over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

There are several kinds of antifungal drugs, out of which in few people can be advised to have over-the-counter (OTC) and few that are prescribed by the physician. Someone who is very weak and has a low immune system and assume to have fungal infection should consult a physician instantly. Yeasts, Molds, and mushrooms are all different kinds of fungi. Fungi can result to a variety of problems. Most of them impact the nails or skin, resulting to rashes or other skin problems, however few can lead to many severe inflammations.

Competitive Landscape:

Key players included in the global antifungal drugs market are Gilead Sciences, Inc., Enzon Pharmaceuticals, Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Limited, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Pfizer Inc., Sanofi S.A., and Astellas Pharma, Inc.    

Market Key Drivers:

The rising fungi infections such as athlete’s foot is expected to propel the growth of global antifungal drugs market. For instance, as per NCBI, around 20% of Adults get affected by the fungal diseases globally.

The increasing cases of AIDS also leads to fungal infection is projected to boost growth of global antifungal drugs market. For instance, as per WHO 48.6 million people suffer from AIDS globally.

Covid-19 Impact Analysis:

The COVID-19 pandemic is projected to hinder the antifungal drugs market during the predicted period. The COVID-19 virus has spread globally on the earth as its discovery in December 2019, led the WHO to declare it as a public clinical emergency. In the pneumonia cases, COVID-19, a new Covid-19, was ensured as the relevant disease. This virus rapidly spread globally, killing many people.

Key Takeaways:

The global antifungal drugs market is anticipated to exhibit a CAGR of XX % during the forecast period owing to rising collaborations for the expansion of pharma products. For instance, CARB-X, a public-private collaboration, is projected to offer over US$ 350 million in the upcoming years to increase the R&D.

Among regions, North America, Europe and Asia Pacific are expected to witness robust growth in global antifungal drugs market due to rising usage of drugs, quick launches and approvals, rising disposable income and rising adoption by the key players. For instance, In addition, in July 2018, Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. declared introduction of NAILIN oral antifungal drugs in Japan for the therapy of onychomycosis.